Clinical Trials
Basket Trials
Boehringer Ingelheim Study 1479-0009-Beamion PANTUMOR-1
Study:
A Phase II, multicenter, multi-cohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumors.
Breakdown:
This study is testing an investigational medication called zongertinib, taken by mouth, to see how safe and effective it is in treating certain types of cancers that have changes in a gene called HER2. If your tumor has a HER2 mutation or overexpression (too much HER2 protein), you may be eligible to join. This includes cancers like lung, breast, and other solid tumors.
ClinicalTrials.gov ID: NCT06581432
Seagen SGNB6A-001
Study:
A Phase 1 Study of SGN-B6A in Advanced Solid Tumors.
Breakdown:
This study is testing an experimental cancer drug called SGN‑B6A, which is an antibody drug conjugate targeting integrin B6 on cancer cells. It is internalized by the cancer cells and then releases the cytotoxic drug MMAE, which kills the cancer cells. It’s for people with advanced solid tumors like lung, head and neck, bladder, or ovarian cancer that haven't responded to standard treatments. Researchers want to find the safest dose and see how well it works, either alone or with other cancer therapies.
ClinicalTrials.gov ID: NCT04389632
Breast Trials
Novartis CLEE011O12001
Study:
A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2− early breast cancer (Adjuvant WIDER).
Breakdown:
This study is testing whether adding the drug ribociclib to standard hormone therapy can lower the risk of breast cancer coming back in people with early-stage, hormone receptor-positive, HER2-negative breast cancer. Participants will take ribociclib in cycles (three weeks on, one week off) along with their usual hormone therapy for about three years, with regular check-ups and monitoring. The trial is designed to include a broad range of patients, making it more like real-world medical practice, and aims to see how effective and safe this combination is at preventing cancer recurrence.
ClinicalTrials.gov ID: NCT05827081
Gastric Trials
AstraZeneca D702AC00001- ARTEMIDE
Study:
A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First-line Treatment of HER2-positive Gastric Cancer.
Breakdown:
This study is testing a new treatment combination for adults with HER2-positive stomach or gastroesophageal junction cancer that has not received prior therapy and whose tumors also express the PD‑L1 protein. One group (Arm A) receives rilvegostomig (an immune blocker that targets PD‑1 and TIGIT) together with trastuzumab deruxtecan (T-DXd) and a single chemotherapy drug (either capecitabine or 5‑fluorouracil). The comparison group (Arm B) receives the current standard therapy of trastuzumab plus pembrolizumab (an immune checkpoint inhibitor) and two chemotherapy drugs. A third arm (Arm C) tests rilvegostomig with trastuzumab and chemotherapy to see the impact of each medicine. The goal is to find out if the new combination works better and is as safe or safer than the standard therapy.
ClinicalTrials.gov ID: NCT06764875
Lung Trials
Merck V940-002
Study:
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer.
Breakdown:
This study is exploring whether adding a personalized mRNA vaccine named V940 to the immunotherapy pembrolizumab can help prevent lung cancer from returning after surgery and chemotherapy in adults with stage II to III non‑small cell lung cancer. Participants will be randomly assigned to receive either the vaccine plus pembrolizumab or a placebo plus pembrolizumab. The main purpose is to see if the combination can extend the time patients remain cancer‑free compared to pembrolizumab alone. The vaccine is tailored to each person’s tumor genetics, helping train the immune system to recognize and attack any remaining cancer cells.
ClinicalTrials.gov ID: NCT06077760
AstraZeneca D7632C00001 – TROPION Lung10
Study:
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10).
Breakdown:
This study is testing new treatment options for adults with advanced non-squamous non-small cell lung cancer that has high PD-L1 levels (50% or more) and no certain gene mutations such as EGFR, ALK, or ROS1. Participants are randomly assigned to receive either datopotamab deruxtecan (a targeted chemotherapy) plus rilvegostomig (a new dual-target immunotherapy), rilvegostomig alone, or pembrolizumab alone, which is a current standard treatment. All treatments are given by IV every three weeks and continued as long as they are working and side effects are manageable. The main goal is to see if the new drug combinations can help patients live longer or keep their cancer from growing longer than the current standard therapy, while also tracking side effects and quality of life.
ClinicalTrials.gov ID: NCT06357533
BioNTech BNT327-06
Study:
A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer.
Breakdown:
This study is for adults with advanced non-small cell lung cancer (NSCLC) who are starting first-line treatment. Participants receive an experimental immunotherapy drug called BNT327 together with standard chemotherapy (either pemetrexed or paclitaxel plus carboplatin), and in some cases pembrolizumab as well. The phase II part tests two different doses of BNT327 to find the safest and most effective level; once the best dose is determined, the study moves to phase III to compare outcomes in more patients. Treatment is given every three weeks, and patients are monitored for how well the drugs shrink the cancer, what side effects occur, and overall health and quality of life. Results will help determine whether adding BNT327 can improve treatment outcomes for people with advanced NSCLC.
ClinicalTrials.gov ID: NCT06712316
AstraZeneca D967SC00001 –DESTINY 04
Study:
An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04).
Breakdown:
This study tests whether the antibody‑drug conjugate trastuzumab deruxtecan (T‑DxD) can be more effective and safe than standard first-line treatment for adult patients with unresectable or metastatic non‑small cell lung cancer that contains HER2 mutations in exon 19 or 20 and who have not yet received systemic therapy for advanced disease. Participants are randomly assigned to receive either T‑DxD by itself or standard therapy with a combination of chemotherapy (cisplatin or carboplatin + pemetrexed) plus the immunotherapy pembrolizumab. The study checks whether T‑DxD helps patients live longer without cancer worsening and improves survival, while also measuring side effects and quality of life.
ClinicalTrials.gov ID: NCT05048797
Daiichi Sankyo, Inc. DS8201-793
Study:
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Platinum-based Chemotherapy in Combination with Pembrolizumab, as First-line Therapy in Participants with Locally Advanced Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06).
Breakdown:
This study evaluates a new treatment approach for adults with advanced non‑squamous lung cancer that overexpresses HER2 and has lower PD‑L1 levels (under 50%). For the first treatment, participants are randomly assigned to receive either trastuzumab deruxtecan (Enhertu) combined with pembrolizumab, or the current standard of pembrolizumab with platinum-based chemotherapy. Both treatments are given intravenously every three weeks. The goal is to determine whether the newer combination can help patients live longer, keep the cancer from worsening, and possibly offer fewer or more manageable side effects compared to standard therapy.
ClinicalTrials.gov ID: NCT06899126
AstraZeneca D419ML00003 – TRITON
Study:
A Phase IIIb, Randomized, Multicenter, Open-label Study, to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Comutations in STK11, KEAP1, or KRAS (TRITON).
Breakdown:
This study is for adults with metastatic non‑small cell lung cancer of the non‑squamous type whose tumors have specific gene mutations (STK11, KEAP1, or KRAS). These mutations often make standard treatments less effective. Participants are randomly assigned to receive either durvalumab plus tremelimumab with chemotherapy (pemetrexed plus cisplatin or carboplatin) or the usual treatment of pembrolizumab with chemotherapy, given through IV every three weeks. The study will compare how long patients live, how long their cancer stays under control, how well each treatment reduces tumors, and their side effects and overall quality of life. It aims to see if the durvalumab + tremelimumab combination can work better than standard therapy in this group of patients with certain genetic mutations.
ClinicalTrials.gov ID: NCT06008093
Genentech CO45042 – KRAScendo-2
Study:
A Phase III, Randomized, Open-label Study Evaluating the Efficacy and Safety of Divarasib Plus Pembrolizumab Versus Pembrolizumab Plus Pemetrexed and Carboplatin or Cisplatin in Patients with Previously Untreated, KRAS G12C-Positive, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer.
Breakdown:
This study is for adults with advanced non‑small cell lung cancer (NSCLC) that has not been treated before and carries a specific KRAS mutation known as G12C. Participants are randomly placed into one of two groups: one receives an experimental targeted drug called divarasib (an oral pill) combined with pembrolizumab (a standard immunotherapy given by IV), and the other group receives the current standard first-line therapy of pembrolizumab along with platinum-based chemotherapy (cisplatin or carboplatin plus pemetrexed). Treatment continues every three weeks until the cancer progresses or side effects become intolerable. The main goal is to find out whether adding divarasib can help patients live longer and keep their cancer from growing compared to standard therapy, while monitoring side effects and quality of life.
ClinicalTrials.gov ID: NCT06793215
Bristol-Myers Squibb - BMS CA209-1533
Study:
A Phase II, Open-label, Randomized Trial to evaluate two doses of subcutaneous formulation of nivolumab in combination with intravenous Ipilimumab and chemotherapy in participants with previously untreated metastatic or recurrent non-small cell lung cancer.
Breakdown:
This study is for adults with newly diagnosed metastatic or recurring non-small cell lung cancer (NSCLC) who haven’t had prior treatment. The study compares two ways of giving immunotherapy: nivolumab injected under the skin at two different schedules, combined with ipilimumab given intravenously along with chemotherapy (such as carboplatin, cisplatin, paclitaxel, or pemetrexed). The goal is to find out which dosing schedule works best and is safe, and whether the combination helps control cancer, improve survival, and maintain quality of life. Participants and doctors know which treatments are being given (open-label).
ClinicalTrials.gov ID: NCT06946797
Bristol-Myers Squibb - BMS CA240-0029
Study:
A Randomized Phase II/III Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy vs Chemotherapy in First Line Metastatic NSCLC (mNSCLC) Participants with Homozygous MTAP Deletion.
Breakdown:
This study is investigating a new treatment for adults with first-time metastatic non-small cell lung cancer (NSCLC) whose tumors have a specific genetic change called homozygous MTAP deletion, and who have not yet received treatment. Patients are randomly assigned to receive either the experimental drug BMS‑986504 (an oral targeted therapy) along with pembrolizumab (an immunotherapy) and chemotherapy, or a placebo plus pembrolizumab and chemotherapy. The study will measure whether adding BMS‑986504 helps patients live longer, keeps their cancer from progressing, and is as safe or better tolerated than the standard treatment. It also monitors for side effects and overall quality of life.
ClinicalTrials.gov ID: NCT07063745
Bristol-Myers Squibb - BMS CA240-0009
Study:
A Multicenter, Randomized, Open-label, Phase II study evaluating the Safety and Efficacy of BMS-986504 Monotherapy in participants with Advanced or Metastatic NSCLC w/ homozygous MTAP Deletion after progression on prior therapies.
Breakdown:
This study is for adults whose advanced non-small cell lung cancer (NSCLC) has progressed after previous treatments and whose tumors carry a rare genetic change called homozygous MTAP deletion. In this open-label trial, participants receive the experimental oral medication BMS‑986504 alone (no chemotherapy or immunotherapy) to assess whether the drug is safe and whether it helps control the cancer when other treatments have stopped working. The study aims to gather early evidence about how well nearly 130 participants tolerate the drug and if it slows tumor growth or provides benefit in this specific type of lung cancer. Adults must be able to swallow tablets, have measurable disease, and meet health performance criteria to join.
ClinicalTrials.gov ID: NCT06855771
Lymphoma Trials
Celgene - BMS CA073-1020 (GOLSEEK-1)
Study:
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma.
Breakdown:
This is a global Phase III study testing whether adding a new oral drug called golcadomide to the standard R‑CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) improves outcomes for people with previously untreated, high-risk large B‑cell lymphoma, a fast-growing type of blood cancer. Participants are randomly assigned to receive either golcadomide + R‑CHOP or placebo + R‑CHOP. The study will look at how well the addition works at extending the time without cancer progression and overall survival, as well as checking for safety and side effects.
ClinicalTrials.gov ID: NCT06356129
Genentech GO44145 (SkyGlo)
Study:
A Phase III, multicenter, randomized, open-label study comparing the efficacy & safety of Glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, & prednisone (POLA-R-CHP) vs POLA-R-CHP in previously untreated patients with Large B-Cell Lymphoma.
Breakdown:
This study is for adults with newly diagnosed large B‑cell lymphoma (a common type of aggressive blood cancer) and no prior treatment. Participants are randomly assigned to receive either the standard chemotherapy regimen called Pola‑R‑CHP (which includes rituximab, polatuzumab vedotin, cyclophosphamide, doxorubicin, and prednisone) with the experimental drug glofitamab, or Pola‑R‑CHP alone. Glofitamab is a novel antibody therapy that helps the body’s immune cells target and kill lymphoma cells. The trial spans about 6–8 treatment cycles over several months, and participants are followed for several years overall. The main goal is to see whether adding glofitamab helps delay cancer progression, improve survival, and maintain quality of life, while also evaluating safety compared to the standard treatment.
ClinicalTrials.gov ID: NCT06047080
Genentech GO45434
Study:
A Phase II, Open-label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitimab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Breakdown:
This study is for adults whose diffuse large B-cell lymphoma (DLBCL) has returned or not responded to previous treatment. It explores giving a combination of glofitamab, gemcitabine, and oxaliplatin (known as Glofit‑GemOx), followed by glofitamab alone. The main purpose is to see how often and how severely patients experience cytokine release syndrome (CRS)—a potential immune reaction that can cause symptoms like fever or rapid heartbeat—when treated with this combination. Patients receive these drugs through IV infusions every three weeks and use additional medications like obinutuzumab and steroids beforehand to reduce the risk of CRS. The study will monitor safety, side effects, and cancer response over treatment cycles and several years of follow-up.
ClinicalTrials.gov ID: NCT06806033
Celgene - BMS CA073-1003 (GOLSEEK-4)
Study:
A Phase III, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma.
Breakdown:
This study is testing whether adding a new oral drug called golcadomide to rituximab is better than the current treatments for adults whose follicular lymphoma has returned or not responded after at least one prior therapy. Patients are randomly assigned to receive golcadomide plus rituximab or one of the standard regimens. The goal is to find out if the new combination is more effective at controlling the cancer and has acceptable side effects compared to existing options. The study plans to enroll about 400 participants globally, and results will include measures like how long the cancer stays under control, overall response rates, safety, and quality of life.